Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Qiwen Ben

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0344-5617; OpenAlex author ID A5083041058. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper

Papers 16

  1. GATA6-AS1 suppresses epithelial-mesenchymal transition of pancreatic cancer under hypoxia through regulating SNAI1 mRNA stability. Co-author DOI 10.1186/s12967-023-04757-5↗
  2. Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.04.004↗
  3. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-020-01689-6↗
  4. Cigarette Smoking and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1097/mpa.0000000000001383↗
  5. Effect of p53 on pancreatic cancer-glucose tolerance abnormalities by regulating transglutaminase 2 in resistance to glucose metabolic stress. Co-author DOI 10.18632/oncotarget.19402↗
  6. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. Co-author DOI 10.1080/15384101.2015.1127471↗
  7. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000271↗
  8. High neuropilin 1 expression was associated with angiogenesis and poor overall survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000117↗
  9. Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells in vitro. Co-author DOI 10.3892/etm.2014.1519↗
  10. Clinical profiles and long-term outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus. Co-author DOI 10.1002/dmrr.1284↗
  11. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Co-author DOI 10.1093/carcin/bgs002↗
  12. Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: a case-control study from China. Co-author DOI 10.1097/mpa.0b013e31822ca176↗
  13. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma. First author DOI 10.1245/s10434-012-2407-2↗
  14. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Co-author DOI 10.1002/ijc.25426↗
  15. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Co-author DOI 10.1016/j.ejca.2010.07.010↗
  16. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Co-author DOI 10.1016/j.ejca.2011.03.003↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yaozong Yuan · 12 shared papers, 2011–2020 · strength 0.75
  2. Yunwei Sun · 3 shared papers, 2019–2020 · strength 0.37
  3. Duowu Zou · 3 shared papers, 2019–2020 · strength 0.37
  4. Wei An · 4 shared papers, 2012–2020 · strength 0.25
  5. Yunhui Zhou · 1 shared paper, 2023 · strength 0.19
  6. Lin Zhou · 1 shared paper, 2023 · strength 0.19
  7. Lifu Wang · 2 shared papers, 2015–2019 · strength 0.17
  8. Zhaoshen Li · 5 shared papers, 2011–2012 · strength 0.16
  9. Zhao‐Shen Li · 3 shared papers, 2011–2016 · strength 0.14
  10. Kaixuan Wang · 4 shared papers, 2011–2012 · strength 0.13
  11. Xiaoyan Ning · 3 shared papers, 2011–2016 · strength 0.11
  12. Jian Fei · 2 shared papers, 2014 · strength 0.09
  13. Xiangyi He · 2 shared papers, 2012–2017 · strength 0.09
  14. Jun Gao · 2 shared papers, 2012–2016 · strength 0.08
  15. Jianming Zheng · 2 shared papers, 2012–2014 · strength 0.08
  16. Xiao Hua Su · 1 shared paper, 2017 · strength 0.06
  17. Ping Chen · 1 shared paper, 2017 · strength 0.06
  18. Wei‐Guang Li · 1 shared paper, 2017 · strength 0.06
  19. Yi Zang · 1 shared paper, 2017 · strength 0.06
  20. Weiyan Yao · 1 shared paper, 2017 · strength 0.06
  21. Quan-cai Cai · 2 shared papers, 2011–2012 · strength 0.06
  22. Hua-gao Zhang · 2 shared papers, 2011–2012 · strength 0.06
  23. Hongyu Wu · 1 shared paper, 2016 · strength 0.05
  24. Yiqi Du · 1 shared paper, 2016 · strength 0.05
  25. Yan-fang Gong · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.